Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study
about
SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectivesCardiovascular Effects of Glucagon-Like Peptide-1 Receptor AgonistsAdverse Effects of GLP-1 Receptor AgonistsGlucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndromeClinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature ReviewCardiovascular effects of incretin therapy in diabetes care.Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational studyLiraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study.Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways.Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitusDecreased urine uric acid excretion is an independent risk factor for chronic kidney disease but not for carotid atherosclerosis in hospital-based patients with type 2 diabetes: a cross-sectional studyEffect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study.Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis.Effectiveness of Liraglutide in Type II Diabetes Mellitus Management: Experience in Emirati Patients.Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes.Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.Lipid effects and cardiovascular disease risk associated with glucose-lowering medications.A Plethora of GLP-1 Agonists: Decisions About What to Use and When.Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes.Exenatide Inhibits the KCa3.1 Channels of Aortic Vascular Smooth Muscle in Diabetic Rats.Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB.Liraglutide attenuates atherosclerosis via inhibiting ER-induced macrophage derived microvesicles production in T2DM rats.Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.Cardiovascular effects of glucagon-like peptide-1 receptor agonist therapies in patients with type 1 diabetes.Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives.Real-life achievement of lipid-lowering treatment targets in the DIAbetes and LifEstyle Cohort Twente: systemic assessment of pharmacological and nutritional factors.Role of the CHADS Score in the Evaluation of Carotid Atherosclerosis in Patients with Atrial Fibrillation Undergoing Carotid Artery Ultrasonography
P2860
Q26746901-5613800D-9063-434B-AB30-8B2BAC323ECBQ26749495-6EA1F649-DFCA-4BA9-9F9C-D737B797B1B4Q26801346-37CA09FB-110F-456D-9028-9B95CE22415FQ28070416-CD5C2C48-87EF-4C99-A376-BB72F1C78479Q28079191-B54C7550-E05A-4B48-9E52-22A41DD99081Q34171759-2B0A5E1F-823E-457A-86CD-5268077DEA02Q34202922-2C34D72A-7A8D-4378-B1B7-73D59D58BDADQ35055133-4DED9171-6833-4C9F-B58C-14229712103DQ35082511-6AEA92AA-3676-4732-8117-EEC18E06CD12Q35117779-7C989AF3-E504-4693-A6AC-D13D5E46A093Q35518966-F2C98130-C424-4E4D-8190-A5ECB3F6EE75Q35532329-30B2F836-D754-43C3-BB54-D4C46117A999Q35784692-96D4ECE2-D613-4B6E-B611-D2AE6FD8DFB8Q36082402-96457B9F-3A57-484D-8A1D-A28ED7EAC457Q36302662-E1106B26-8FCC-4A67-88AD-4F8CDB53DB27Q37470522-32956672-0DD6-4294-B314-5BF5DA7B9783Q38511039-309A71F0-E05B-409B-90EB-BFAAFE926631Q38987110-5BD82290-1EDF-46ED-ADD0-4B42A43EFBAAQ39320400-1A149407-F393-4CD6-974C-B5A4E92F01DEQ40432883-B970EEF7-F686-41D9-B9D9-C3EA4EC543BBQ47096372-D533AF25-D07B-4257-A7A3-6E9408245F0DQ47109213-D7CB6A9D-678C-4A8F-BBF7-FAA61198EC6EQ47152819-ED5B1272-8D9B-4CF5-A2CE-C0FB989E74C5Q48331707-3F81E1C1-8FD3-48BF-9221-5AA21AC99948Q48340758-866A38D9-49F3-4C82-AE3C-4E18BB8C7701Q48664757-613F8E5E-D937-4F5A-98C8-A9224A8CA20DQ52562837-88E6415F-BCC2-4F0D-B3FB-2B117ECEFC1FQ58766109-3113E536-063C-49F1-843C-94C06E2D60D7
P2860
Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Liraglutide decreases carotid ...... -month prospective pilot study
@en
Liraglutide decreases carotid ...... month prospective pilot study.
@nl
type
label
Liraglutide decreases carotid ...... -month prospective pilot study
@en
Liraglutide decreases carotid ...... month prospective pilot study.
@nl
prefLabel
Liraglutide decreases carotid ...... -month prospective pilot study
@en
Liraglutide decreases carotid ...... month prospective pilot study.
@nl
P2093
P2860
P356
P1476
Liraglutide decreases carotid ...... -month prospective pilot study
@en
P2093
Ali A Rizvi
Angelo Maria Patti
Manisha Chandalia
Nicola Abate
Vittoria Di Bartolo
P2860
P2888
P356
10.1186/1475-2840-13-49
P407
P577
2014-02-22T00:00:00Z
P5875
P6179
1039287431